Recognition of Extraordinary Income and Loss for the Fiscal Year Ending April 2026
The silent partnership operated by consolidated subsidiary ケイセブン・ヘルスケア合同会社, and consolidated subsidiary 株式会社Fanta
Real estate held for sale (trust beneficiary rights), healthcare facilities, ケイシックス silent partnership interests, and ケイセブン silent partnership interests
The transfer of real estate held for sale (trust beneficiary rights) by a silent partnership operated by ケイセブン・ヘルスケア合同会社, and the transfer of silent partnership interests associated with the sale of healthcare facilities
Gain on sale of fixed assets of ¥97.214 million (extraordinary income), and loss on sale of investment securities of ¥292.513 million (extraordinary loss)
Fiscal year ending April 2026
These extraordinary income and loss have been reflected in the “Financial Results Summary for the Fiscal Year Ending April 2026 [Japanese GAAP] (Consolidated).” The transactions as a whole will have a positive impact on profit for the period for the fiscal year ending April 2026.
| Item | Details |
|---|---|
| Event name | Recognition of Extraordinary Income and Loss for the Fiscal Year Ending April 2026 |
| Subject Entity | The silent partnership operated by consolidated subsidiary ケイセブン・ヘルスケア合同会社, and consolidated subsidiary 株式会社Fanta |
| Target Locations / Products | Real estate held for sale (trust beneficiary rights), healthcare facilities, ケイシックス silent partnership interests, and ケイセブン silent partnership interests |
| Cause | The transfer of real estate held for sale (trust beneficiary rights) by a silent partnership operated by ケイセブン・ヘルスケア合同会社, and the transfer of silent partnership interests associated with the sale of healthcare facilities |
| Amount of Impact on Business Performance | Gain on sale of fixed assets of ¥97.214 million (extraordinary income), and loss on sale of investment securities of ¥292.513 million (extraordinary loss) |
| Accounting period in which recognized | Fiscal year ending April 2026 |
| Impact on Earnings Forecast | These extraordinary income and loss have been reflected in the “Financial Results Summary for the Fiscal Year Ending April 2026 [Japanese GAAP] (Consolidated).” The transactions as a whole will have a positive impact on profit for the period for the fiscal year ending April 2026. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The extraordinary income arose from the transfer of real estate held for sale (trust beneficiary rights) by a silent partnership operated by ケイセブン・ヘルスケア合同会社. The extraordinary loss arose because 株式会社Fanta transferred its silent partnership interests in connection with the sale of healthcare facilities carried out as part of a review of the business portfolio.